	US 12,421,292 B2
	Anti-DLL3 chimeric antigen receptors and uses thereof
Tao Zhao, Nanjing (CN); Yuanyuan Peng, Nanjing (CN); An Tang, Nanjing (CN); Sujuan Wang, Nanjing (CN); Shuai Yang, Nanjing (CN); Wang Zhang, Nanjing (CN); Shu Wu, Nanjing (CN); and Ruidong Hao, Shanghai (CN)
Assigned to Legend Biotech Ireland Limited, Dublin (IE)
Appl. No. 17/618,642
Filed by Legend Biotech Ireland Limited, Dublin (IE)
PCT Filed Jul. 17, 2020, PCT No. PCT/CN2020/102717 § 371(c)(1), (2) Date Dec. 13, 2021, PCT Pub. No. WO2021/008610, PCT Pub. Date Jan. 21, 2021.
Claims priority of application No. PCT/CN2019/096360 (WO), filed on Jul. 17, 2019; and application No. PCT/CN2020/090587 (WO), filed on May 15, 2020.
Prior Publication US 2022/0249563 A1, Aug. 11, 2022
Int. Cl. A61K 40/31 (2025.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C07K 16/18 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/70521 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4229 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 16/18 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C07K 2317/22 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01)]

6 Claims

1. A chimeric antigen receptor (CAR) that specifically binds to DLL3, wherein the CAR comprises a first single domain antibody (sdAb) moiety and a second sdAb moiety, wherein:

(a) the first sdAb moiety comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 6; a CDR2 comprising the amino acid sequence of SEQ ID NO: 87; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 168; and

(b) the second sdAb moiety comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 21; a CDR2 comprising the amino acid sequence of SEQ ID NO: 102; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 183.